First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

TRAX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

First Tracks Biotherapeutics IncNASDAQ: TRAX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $33.96M fell 18.1% year over year.

Context

  • Research & development increased in 1 of the last 2 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.96M— QoQ
Last fiscal yearDec 2025
$139.61M-8.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.1%——
1 year-8.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
139.61M USD
Year-over-year change
-8.4%
2-year CAGR
+19.6%

Research & Development vs competitors

How TRAX compares with its peers on the latest reported figures

  • TRAX's FY2025 research & development of $139.61M is the 3rd highest of the 10 companies compared; the peer median is $69.93M.
  • Its year-over-year change of -8.4% is the 8th highest of 10, against a peer median of +20.4%.
TRAX Competitors Peer median
Research & Development for TRAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$468.85M +16.2%+41.8%6608.2%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$220.82M +62.1%+69.0%—
TRAXFirst Tracks Biotherapeutics IncFY2025$139.61M -8.4%——
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M -23.4%+15.3%55.4%
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$69.93M +20.4%+34.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M +60.6%-12.2%677.9%
ATTOAttovia Therapeutics, Inc.FY2025$54.15M +59.9%—4011.3%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$49.22M +63.5%-1.9%—
CLYMClimb Bio, Inc.LTM Mar 2026$38.72M -52.9%+21.2%—
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding TRAX) $69.93M+20.4%+18.2%2344.6%

Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue0152.35M139.61M
Gross Profit0(152.35M)(139.61M)
Gross Margin———
Research & Development97.59M152.35M139.61M
Selling, General & Admin20.87M28.76M39.39M
Operating Expenses118.46M28.76M39.39M
Depreciation & Amortization2.38M2.4M559K
EBITDA(116.09M)(178.7M)(178.45M)
EBITDA Margin———
Operating Income(118.46M)(181.1M)(179.01M)
Operating Margin———
Interest Income12.31M17.38M0
Interest Expense000
Other Income / Expenses12.31M17.4M12.92M
Income Before Tax(106.15M)(163.71M)(166.09M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(106.15M)(163.71M)(166.09M)
Net Margin———
EPS (Basic)(3.05)0.000.00
EPS (Diluted)(3.05)0.000.00
Weighted Avg Shares34.75M00
Weighted Avg Shares (Diluted)34.75M00

First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Intrinsic Alpha fair value

Locked

Current Price

$44.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.